PV-1950R / Capo Therap, University of California - LARVOL DELTA

Novel pilot Phase 1 clinical trial with PV-1950R/A vaccine for Lewy Body Dementia (LBD) (CTAD 2024) - No abstract available

Clinical • P1 data • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease

A novel dementia vaccine targeting three B cell epitopes of Pathological α-Synuclein (PRNewswire) - "A potential preventive vaccine against Dementia Lew Body and Parkinson's disease moves from the mouse model of Synucleinopathies to the IND enabling studies....The most effective nucleic acid vaccine, PV-1950D, generated antibodies specific to three regions of α-Synuclein simultaneously, reduced the aggregation of this pathological molecule, and improved motor deficits in the mouse model of disease. In a new study...two co-first-author scientists from IMM, Karen Zagorsky, Ph.D., and Gor Chailyan, Ph.D., along with the team of collaborators from IMM, UCI, and the Laboratory of Neurogenetics, NIA, report on the development of the same vaccine in the form of the recombinant protein, PV-1950R, formulated in adjuvant."

Preclinical • CNS Disorders • Parkinson's Disease

A novel dementia vaccine targeting three B cell epitopes of Pathological α-Synuclein (PRNewswire) - "Early this year, the scientists from the Institute for Molecular Medicine (IMM), their collaborators from the University of California, Irvine (UCI), and the National Institute on Aging (NIA) reported on the efficacy of four DNA vaccines based on the universal MultiTEP platform and targeting various regions of pathological α-Synuclein in a mouse model of Dementia Lewy Body (DLB) and Parkinson disease (PD) (PMID: 35013319). The most effective nucleic acid vaccine, PV-1950D, generated antibodies specific to three regions of α-Synuclein simultaneously, reduced the aggregation of this pathological molecule, and improved motor deficits in the mouse model of disease...along with the team of collaborators from IMM, UCI, and the Laboratory of Neurogenetics, NIA, report on the development of the same vaccine in the form of the recombinant protein, PV-1950R...'we will manufacture cGMP PV-1950R drug product and use it in IND-enabling safety/ toxicology studies...'"

Clinical • Preclinical • CNS Disorders • Dementia • Lewy Body Disease • Parkinson's Disease

Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein. (PubMed, Int J Mol Sci) - "However, to ensure therapeutically potent concentrations of α-Syn antibodies in the periphery of the vaccinated elderly, we developed a recombinant protein-based MultiTEP vaccine, PV-1950R/A, and tested its immunogenicity in young and aged D-line mice. Antibody responses induced by immunizations with the PV-1950R/A vaccine and its homologous DNA counterpart, PV-1950D, in a mouse model of PD/DLB have been compared."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Immunology • Inflammation • Lewy Body Disease • Movement Disorders • Parkinson's Disease